<DOC>
	<DOCNO>NCT00000676</DOCNO>
	<brief_summary>To study effectiveness , safety , tolerance fluconazole versus clotrimazole troche ( lozenge ) prophylaxis ( preventive treatment ) fungal infection patient enrol ACTG 081 ( study prophylaxis pneumocystosis , toxoplasmosis , serious bacterial infection ) . Primarily , compare rate invasive infection C. neoformans , endemic mycoses , Candida . To compare mortality rate due fungal infection two antifungal prophylactic treatment . Secondarily , assess effect prophylaxis incidence severe fungal infection , define invasive infection esophageal candidiasis less severe mucocutaneous infection . Serious fungal infection significant complicate life-threatening occurrence patient advance HIV infection . Oropharyngeal candidiasis find almost patient , cause pain , difficulty swallowing , loss appetite . Similarly , esophageal candidiasis cause illness population . Cryptococcosis , endemic mycoses , coccidioidomycosis also cause significant illness death AIDS patient . Once establish , fungal infection AIDS patient generally require continuous suppressive therapy attempt cure infection usually unsuccessful . Fluconazole number characteristic would make logical candidate examine prophylactic agent patient advance HIV infection . Animal study show prophylactic model candidiasis , cryptococcosis , histoplasmosis , coccidioidomycosis . Initial experience patient active cryptococcal meningitis appear favorable , study oropharyngeal candidiasis show effective .</brief_summary>
	<brief_title>Randomized Comparative Study Fluconazole Versus Clotrimazole Troches Prevention Serious Fungal Infection Patients With AIDS Advanced AIDS-Related Complex . ( A Nested Study ACTG 081 )</brief_title>
	<detailed_description>Serious fungal infection significant complicate life-threatening occurrence patient advance HIV infection . Oropharyngeal candidiasis find almost patient , cause pain , difficulty swallowing , loss appetite . Similarly , esophageal candidiasis cause illness population . Cryptococcosis , endemic mycoses , coccidioidomycosis also cause significant illness death AIDS patient . Once establish , fungal infection AIDS patient generally require continuous suppressive therapy attempt cure infection usually unsuccessful . Fluconazole number characteristic would make logical candidate examine prophylactic agent patient advance HIV infection . Animal study show prophylactic model candidiasis , cryptococcosis , histoplasmosis , coccidioidomycosis . Initial experience patient active cryptococcal meningitis appear favorable , study oropharyngeal candidiasis show effective . AMENDED : 11/01/90 Sufficient number patient enrol center start week 8 participation parent study achieve total 240 evaluable patient remain nested study maximum duration 45 month . Enrollment continue eligible interested 081 patient enrol . Fungal prophylaxis begin time enrollment nest study continue efficacy safety end point reach , withdrawal nest study , death . Original design : Patients include already enrol ACTG 081 . Patients enrol center either week 8 , 12 , 16 , 20 , 24 , 28 , 32 participation parent study . They randomize receive either oral fluconazole clotrimazole troche . Prophylaxis continue serious fungal infection develop , end parent study reach ( expect December 1991 ) , patient withdraws either nest parent study , patient dy . Clinical examination perform 2 week monthly ( clinically indicate ) duration antifungal prophylaxis ; schedule evaluation parent study . There 1-month postprophylaxis follow-up discontinuation prophylaxis reason .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>AIDS-Related Complex</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Required : Zidovudine ( AZT ) . Antipneumocystis prophylaxis . Allowed : Topical suppressive antifungal agent . Eligibility requirement : Participation NIAID ACTG 081 . No history systemic fungal infection , include esophageal systemic candidiasis , cryptococcosis , histoplasmosis , coccidioidomycosis , blastomycosis , sporotrichosis , aspergillosis . Willingness sign inform consent . Transaminases &lt; 5 x upper limit normal . Noncompliance reason withdrawal patient study , unless patient refuse treatment . Allowed : A history oropharyngeal , vaginal cutaneous candidiasis . Dermatophyte infection ( i.e. , tinea pedis ) entry active candida infection . Sites suspect dermatophyte involvement foot candida exclude culture . Prior Medication : Allowed : Topical suppressive antifungal agent . Exclusion Criteria Coexisting Condition : Patients follow condition disease exclude : History systemic fungal infection , include esophageal systemic candidiasis , cryptococcosis , histoplasmosis , coccidioidomycosis , blastomycosis , sporotrichosis , aspergillosis . Active systemic fungal infection time enrollment . Active superficial fungal infection time entry . ( Such patient may treat topical antifungal agent may randomize clinical remission 14 day completion therapy . ) Concurrent Medication : Excluded : Amphotericin B. Fluconazole . Itraconazole . SCH 39304 . Other systemic antifungal . Patients follow exclude : Previous currently active systemic fungal infection . History allergy intolerance imidazole azoles . Positive serum cryptococcal antigen titer dilution . Requiring multiagent therapy tuberculosis symptomatic Mycobacterium avium infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Mycoses</keyword>
	<keyword>Fluconazole</keyword>
	<keyword>Clotrimazole</keyword>
	<keyword>Antifungal Agents</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
</DOC>